Recent news reports highlight uncertainty about pharmaceutical tariffs, an error-prone AI tool in use at the FDA, and scientific research funding in jeopardy.

The FDA has granted accelerated approval to Modeyso (dordaviprone) for the treatment of certain patients with diffuse midline glioma.

The FDA has expanded the approved indication of IV Avtozma to include the treatment of CRS in patients 2 years of age and older.

Future prospective studies will be necessary to assess potential causation of sucralose in driving immunotherapy resistance as well as to determine how other demographic factors, including location ...

Resection beyond contrast-enhancing tumor margins is associated with superior outcomes in patients with primary glioblastoma, a study suggests.

Black men with newly diagnosed prostate cancer have lower odds of overtreatment and confirmatory testing when compared to their White counterparts, data suggest.

The FDA issued another complete response letter for odronextamab for the treatment of relapsed/refractory follicular lymphoma.

The US Food and Drug Administration (FDA) has granted fast track designation to ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) for the treatment of non-small cell lung cancer (NSCLC).